drugset / Trial / NCT00826280

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280

Phase 3 Completed 347 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindDiagnostic

Summary

Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI

Timeline

Start
2009-03-24
Primary completion
2010-07-15
Completion
2010-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule 200 mg Oral
Subject Caffeine Small molecule 400 mg Oral
Background Regadenoson Diagnostic / imaging agent 0.4 mg Intravenous